Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Pharmaceutical Industry Needs to Jump the Curve to Nanotech

Abstract:
In 2003, I wrote the book, "The Next Big Thing is Really Small: How Nanotechnology Will Change the Future of Your Business." In it, I outlined the many ways in which nanotechnology will impact the pharmaceutical industry in the near future. Recently, researchers at Children's Hospital in Boston have uncovered a method of reviving a once-promising cancer drug, TNP-470—which was cancelled in the mid-1990's due to concerns over toxicity.

Pharmaceutical Industry Needs to Jump the Curve to Nanotech

Minneapolis, MN | Posted on July 11th, 2008

The problem of toxicity is not a new one to the pharmaceutical industry. In fact, it is a big reason why so many early stage drugs fail to make it to market.

This vexing problem may soon be partially alleviated due to advances in nanotechnology. One advantage of reformulating drugs at the nanoscale is that they are water soluble and, as such, don't require the solvents which so often cause nasty side-effects in patients.

Another application being employed from the nanotechnology bag of tricks is to use nanoscale platforms such as micelles and dendrimers to prevent drugs from crossing the blood-brain barrier. In this fashion, older drugs may be reformulated so as to prevent certain drugs from wreaking havoc on the human brain. (This was one of the problems with TNP-470).

The pharmaceutical industry has invested billions of dollars developing promising drugs. Unfortunately, most developmental drugs end being shelved when it is found they cause some unintended consequence. Nanotechnology holds the promise that a handful of older drugs may now be revisited. Some may even find their way to the commercial marketplace.

With a single drug's ability to add billions of dollars to a pharmaceutical company's bottom-line, it is time many of them begin turning their attention to nanotechnology. It's a small technology, but it could pay big dividends.

####

About Jack Uldrich
Jack Uldrich is a renowned global futurist, independent scholar, sought-after business speaker, and best-selling author. His books include the best-selling, The Next Big Thing is Really Small: How Nanotechnology Will Change the Future of Your Business, and the award-winning, Into the Unknown: Leadership Lessons from Lewis & Clark’s Daring Westward Expedition. His latest book is Jump the Curve: 50 Essential Strategies to Help Your Company Stay Ahead of Emerging Technologies.

For more information, please click here

Contacts:
Jack Uldrich
612-267-1212

Copyright © Jack Uldrich

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Blog sites

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Nanomedicine

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project